Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis

Pharmacological Research

Volumn 33, Issue 6, 1996, Pages 349-352

  Furlanut, M ^a   Baraldo, M ^a   Galla, F ^a   Marzocchi, V ^a   Pea, F ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Cyclosporin metabolites; Nephrotoxicity; Psoriasis

Indexed keywords

CYCLOSPORIN A; CYCLOSPORIN A [1 (3,8 DIHYDROXY 2 METHYLAMINO 4 METHYL 6 OCTENOIC ACID)]; DRUG METABOLITE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG METABOLISM; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NEPHROTOXICITY; PRIORITY JOURNAL; PSORIASIS;

EID: 0030175140     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1996.0048     Document Type: Article

References (14)

1. 1. Combalbert J, Fabre I, Fahre G, Dalet I, Derancourt J, Cano JP, Maurel P. Metabolism of cyclosporin A. Drug Met Disp 1989; 17: 197-207.
2. 2. Feutren G, Abeywickrama K, Friend D, Von Graffenried B. Renal function and blood pressure in psoriatic patients treated with Cyclosporin A. Br J Dermatol 1990; 122: 57-69.
3. 3. Brown AL, Wilkinson R, Thomas TH, Levell N, Munro C, Marks J, Goodship THJ. The effect of short-term low-dose cyclosporin on renal function and blood pressure in patients with psoriasis. Br J Dermatol 1993; 128: 550-5.
4. 4. Mehring N, Neumann KH, Rahn KH, Zidek W. Mechanism of cyclosporin A induced vasoconstriction in the isolated perfused rat kidney. Nephron 1992; 60: 477-81.
5. 5. Yee GC, Kennedy MS, Self SG, Storb R, Deeg HJ. Pharmacodynamics of Cyclosporine in patients under-going bone marrow transplantation. Transpl Proc 1986; 18: 774-6.
6. 6. Fahar A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472-95.
7. 7. Whitman DA, Abbott V, Fregien K, Bowers LD. Recent advances in high-performance liquid chromatography/mass spectrometry and high-performance liquid chromatography/tandem mass spectrometry: detection of cyclosporine and metabolites in kidney and liver tissue. Ther Drug Monit 1993; 15: 552-6.
8. 8. Harfmann P, Dittmer R, Busch R, Tenschert W, Arndt R. Cyclosporin A-induced side effects in renal transplantation are related to the ratio of nonspecific/specific cyclosporin blood trough levels as analysed by radioimmunoassay. Transpl Proc 1990; 22: 2369-72.
9. 9. Copeland KR, Yatscoff RW. Immunosuppressive activity and toxicity of cyclosporine metabolites characterized by mass spectroscopy and nuclear magnetic resonance. Transpl Proc 1990; 22: 1146-9.
10. 10. Wonigeit K, Kohlhaw K, Winkler M, Schaefer O, Pichlmayr R. Cyclosporine monitoring in liver allograft recipients: two distinct patterns of blood level derangement associated with nephrotoxicity. Transpl Proc 1990; 22: 1305-11.
11. 11. Rosano TG, Pell MA, Freed BM, Dybas MT, Lempert N. Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies. Transpl Proc 1988; 20: 330-8.
12. 12. Galla F, Marzocchi V, Croattino L, Poz D, Baraldo M, Furlanut M. Oral and intravenous disposition of cyclosporine in psoriatic patients. Ther Drug Monit 1995; 17: 302-4.
13. 13. Furlanut M, Baraldo M, Pea F, Marzocchi V, Croattino L, Galla F. Blood concentrations and clinical effect of cyclosporin in psoriasis. Ther Drug Monit (in press).
14. 14. Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkins PB. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 1990; 335: 11-5.